Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Chugai Pharmaceutical
Age
20–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of RA based on the 1987 classification criteria of the American College of Rheumatology (ACR)
Disease duration of 6 months or more
Treated with 8 mg/week of MTX for at least 8 weeks immediately preceding enrollment, and continued on this treatment up to initiation of the study drug
Active disease at enrollment (less than 2 weeks before initiating treatment with a study drug), Which is defined as having at least 6 tender and 6 swollen joints among 49 and 46 joints stipulated by the Japanese Rheumatism Foundation's Drug Evaluation Committee and ESR at least 30 mm/hr and CRP not less than 1.0 mg/dL
You may not be if
Assessed as having Class IV Steinbrocker functional activity in the 4 weeks preceding treatment with the study drug
Treated with infliximab, etanercept or leflunomide in the 12 weeks preceding treatment with the study drug
Received any of the following therapies in the 2 weeks preceding initiation of treatment with the study drug.
1. Administration of any DMARD or immunosuppressant other than MTX
2. Administration of corticosteroids exceeding 10 mg/day as prednisolone
3. Dose escalation or initiation of corticosteroids
Received any of the following therapies in the 4 weeks preceding treatment with the study drug
1. Plasma exchange therapy
2. Surgical treatment (operation, etc.)
Clareo Health | Comparative Study (Double-Blind) of MRA for Rheumatoid Arthritis (RA)
